C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/68 (2006.01)
Patent
CA 2644517
The present invention provides for a method for identifying patients that are suitably treated by a therapy, such as a therapy involving administration of a fluoropyrimidine drug and/or a platinum drug. The method includes determining the expression level of at least one gene selected from a phospholipase 2 (PLA2) gene, a thymidine phosphorylase (TP) gene, and a glutathione S-transferase P1 (GSTP-1) gene in suitable sample isolated from the patient. Overexpression of the gene or genes identifies the patient as not being suitable for the therapy.
La présente invention concerne un procédé permettant d'identifier des patients qui ont été correctement traités par une thérapie telle qu'une thérapie impliquant l'administration d'un médicament à base de fluoropyrimidine et/ou d'un médicament à base de platine. Le procédé consiste à déterminer le niveau d'expression d'au moins un gène choisi parmi les gènes PLA2 (phospholipase), TP (thymidine phosphorylase) et GSTP-1 (glutathione S-transférase) dans un échantillon approprié prélevé chez le patient. Une surexpression du gène ou des gènes désigne un patient pour lequel la thérapie n'est pas appropriée.
Smart & Biggar
University Of Southern California
LandOfFree
Genetic markers for predicting disease and treatment outcome does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genetic markers for predicting disease and treatment outcome, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetic markers for predicting disease and treatment outcome will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2077150